Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski MK, Price RA Jr.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):518-26. Epub 2005 Oct 19.

PMID:
16242256
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.

Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024. Epub 2011 Apr 7.

PMID:
21477939
[PubMed - indexed for MEDLINE]
3.

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, Bahary JP, Morton GC, Parliament MB, Sandler HM.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):932-8. doi: 10.1016/j.ijrobp.2013.07.041. Epub 2013 Oct 8.

PMID:
24113055
[PubMed - indexed for MEDLINE]
4.

Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.

Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84. doi: 10.1016/j.ijrobp.2014.01.015.

PMID:
24661661
[PubMed - indexed for MEDLINE]
5.

Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.

Pervez N, Small C, MacKenzie M, Yee D, Parliament M, Ghosh S, Mihai A, Amanie J, Murtha A, Field C, Murray D, Fallone G, Pearcey R.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):57-64. doi: 10.1016/j.ijrobp.2009.01.048. Epub .

PMID:
19395192
[PubMed - indexed for MEDLINE]
6.

Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.

Pederson AW, Fricano J, Correa D, Pelizzari CA, Liauw SL.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14.

PMID:
21163587
[PubMed - indexed for MEDLINE]
7.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18.

PMID:
20171807
[PubMed - indexed for MEDLINE]
8.

A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.

Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott FJ, Valuckas KP.

Strahlenther Onkol. 2009 Nov;185(11):715-21. doi: 10.1007/s00066-009-1982-z. Epub 2009 Nov 10.

PMID:
19899003
[PubMed - indexed for MEDLINE]
9.

Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.

Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC, Lebesque JV.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1142-52. Epub 2005 Jun 4.

PMID:
15939547
[PubMed - indexed for MEDLINE]
10.

A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients.

Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M, Storme G, Aleknavicius E, Janulionis E, Valuckas KP.

Radiat Oncol. 2013 Sep 4;8(1):206. doi: 10.1186/1748-717X-8-206.

PMID:
24007322
[PubMed - in process]
Free PMC Article
11.

Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.

Deville C, Vapiwala N, Hwang WT, Lin H, Ad VB, Tochner Z, Both S.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1389-96. doi: 10.1016/j.ijrobp.2011.04.041. Epub 2011 Jun 12.

PMID:
21664069
[PubMed - indexed for MEDLINE]
12.

Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.

Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, Valdagni R, Calandrino R, Fazio F.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):392-8. doi: 10.1016/j.ijrobp.2008.08.038. Epub 2008 Dec 4.

PMID:
19056184
[PubMed - indexed for MEDLINE]
13.

Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.

Alongi F, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F, Reggiori G, Clivio A, Cozzi L, Scorsetti M.

Strahlenther Onkol. 2012 Nov;188(11):990-6. doi: 10.1007/s00066-012-0171-7. Epub 2012 Sep 29.

PMID:
23053143
[PubMed - indexed for MEDLINE]
14.

Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.

Cheng JC, Schultheiss TE, Nguyen KH, Wong JY.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):351-7. doi: 10.1016/j.ijrobp.2007.09.043. Epub 2007 Dec 31.

PMID:
18164841
[PubMed - indexed for MEDLINE]
15.

Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.

Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV.

Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):685-91. doi: 10.1016/j.ijrobp.2008.04.063. Epub 2008 Aug 19.

PMID:
18718725
[PubMed - indexed for MEDLINE]
16.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

PMID:
21163590
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1019-34.

PMID:
15752881
[PubMed - indexed for MEDLINE]
18.

Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.

Zilli T, Jorcano S, Rouzaud M, Dipasquale G, Nouet P, Toscas JI, Casanova N, Wang H, Escudé L, Mollà M, Linero D, Weber DC, Miralbell R.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):382-9. doi: 10.1016/j.ijrobp.2010.05.057. Epub 2010 Sep 29.

PMID:
20884129
[PubMed - indexed for MEDLINE]
19.

Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.

Mohan DS, Kupelian PA, Willoughby TR.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):575-80.

PMID:
10701736
[PubMed - indexed for MEDLINE]
20.

Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.

Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):463-71.

PMID:
16168838
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk